Skip to main content

Table 1 Study Patient Characteristics

From: A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity

Authors (reference) Pub. Date Average patient age (years) Per cent Male BSCr (mg/dl) Diabetes (%) Contrast volume (ml) Jadad Score End point (SCr rise) Contrast procedure NAC regimen Hydration regimen
Tepel et al. [10] 07/00 65 NA 2.5 32.5 75 1 0.5 mg/dl 48 h CT 600 mg tablet bid × 4 0.45% 1 ml/kg/h 12 h before, 12 h after
Diaz-Sandoval et al. [11] 02/02 73 80% 1.6 38.9 184 2 0.5 mg/dl or 25% 48 h LHC 600 mg liquid in ginger ale bid × 4 0.45% 1 ml/kg/h 2–12 h before, 12 h after
Briguori et al. [12] 07/02 64 86% 1.5 37.8 197 1 25% 48 h LHC and/or PA and/or PCI 600 mg tablet bid × 4 0.45% 1 ml/kg/h 12 h before, 12 h after
Vallero et al. [13] 09/02 62 NA 1.0 23.0 205 1 0.5 mg/dl or 33% 48 h LHC and/or PCI 600 mg tablet bid × 4 0.45% 1 ml/kg/h 1–2 h before, 24 h after
Shyu et al. [14] 10/02 70 68% 2.8 63.5 117 1 0.5 mg/dl 48 h LHC ± PCI 400 mg powder bid × 4 0.45% 1 ml/kg/h 12 h before, 12 h after
Allaqaband et al. [15] 11/02 70 NA 2.1 48.3 122 3 0.5 mg/dl 48 h LHC ± PCI or PA + PCI 600 mg liquid in cola bid × 4 0.45% 1 ml/kg/h 12 h before, 12 h after
Durham et al. [16] 12/02 71 66% 2.3 48.1 81 3 0.5 mg/dl 48 h LHC 1200 mg liquid in orange juice bid × 2 0.45% 1 ml/kg/h ≤ 12 h before, ≤ 12 h after
Kay et al. [17] 02/03 69 62% 1.3 37.5 125 5 25% 48 h LHC and/or PCI 600 mg tablet bid × 4 0.9% 1 ml/kg/h 12 h before, 6 h after
Loutrianakis et al. [18] 03/03 67 NA 1.9 36.0 147 1 0.5 mg/dl 120–168 h LHC 600 mg bid × 4 0.45% 1 ml/kg/h
Azmus et al. [19] 07/03 67 59% 1.3 49.6 126 5 0.5 mg/dl or 25% 24–48 h LHC or PCI 600 mg powder in water bid × 5 0.9% 1 L pre, 1 L post, or none
Gomes et al. [20] 10/03 65 59% 1.3 51.9 103 4 0.5 mg/dl 48 h LHC or PCI 600 mg bid × 4 0.9% 1 ml/kg/h 12 h before, 12 h after
Nguyen-Ho et al. [21] 11/03 70 NA 1.4 67.5 347 4 25% 48–72 h LHC or PCI 2000 mg liquid in juice bid × 2 or 3 0.45% 75 ml/h ≥ 24 h from enroll
Efrati et al. [22] 12/03 67 90% 1.5 52.9 140 2 25% 24–96 h LHC 1000 mg liquid in cola bid × 4 0.45% 1 ml/kg/h
El Mahmoud et al. [23] 12/03 67 81% 1.9 30.0 177 2 25% 24–48 h LHC 600 mg orally bid × 2 0.9% 1 ml/kg/h
Kefer et al. [24] 12/03 62 77% 1.1 12.5 199 1 0.5 mg/dl or 25% 24 h LHC and/or PCI 1200 mg in 0.9% saline IV over 60 min, 12 h pre 0 h post 0.9% 1 ml/kg/h
MacNeill et al. [25] 12/03 73 86% 1.9 46.5 110 4 25% 72 h LHC ± PCI 600 mg liquid in juice/soda bid ×5 0.45% 1 ml/kg/h 12 h or 2 ml/kg/h 4 h before, 75 ml/h 12 h after
Oldemeyer et al. [26] 12/03 76 55% 1.6 44.9 131 2 0.5 mg/dl or 25% 48 h LHC 1500 mg liquid in soda bid × 4 500 ml D5 20 ml/h 12 h before, 12 h after
Goldenberg et al. [27] 02/04 70 83% 2.0 43.9 116 5 0.5 mg/dl 48 h LHC ± PCI 600 mg liquid in soda tid × 6 0.45% 1 ml/kg/h
Agrawal et al. [28] 04/04 63 68% 1.7 47.8 178 2 0.5 mg/dl or 25% 48 h LHC and/or PCI 800/600/600 mg liquid in soda 12/2 h pre/6 h post 0.45% 1 ml/kg 12 h ± 250 ml bolus before, 12 h after
Fung et al. [29] 05/04 68 70% 2.3 52.8 128 3 0.5 mg/dl or 25% decrease in GFR 48 h LHC or PCI ± PA 400 mg powder tid × 6 0.9% 100 ml/h 12 h before, 12 h after
Ochoa et al. [30] 06/04 71 43% 2.0 55.5 144 4 0.5 mg/dl or 25% 48 h LHC and/or PCI 1000 mg liquid in diet cola bid × 2 0.9% 150 ml/h, ≥ 500 ml 12 h before, ≥ 1000 24 h after
Webb et al. [31] 09/04 70 NA 1.7 34.9 120 5 0.5 mg/dl 48–192 h LHC or PCI ± PA 500 mg in D5NS IV for 15 min, 1 h pre 0.9% 200 ml before, 1.5 ml/kg/h 6 h or discharge (<6 h) after
  1. SCr, serum creatinine; BSCr, baseline serum creatinine; CT, computed tomography; LHC, left heart catheterization; PCI, percutaneous coronary intervention; PA, peripheral angiography; Jadad score, measure of study design quality (0 is the weakest, 5 is the strongest); NAC, N-acetylcysteine; NA, not applicable; bid, twice daily; tid, three times daily; IV, intravenous; h, hour; D5NS, 5% dextrose plus normal saline; 0.9%, normal saline; 0.45%, half-normal saline.